Market capitalization | $76.95m |
Enterprise Value | $37.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.54 |
P/S ratio (TTM) P/S ratio | 11.28 |
P/B ratio (TTM) P/B ratio | 1.83 |
Revenue growth (TTM) Revenue growth | 24.70% |
Revenue (TTM) Revenue | $6.82m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
2 Analysts have issued a InspireMD Inc forecast:
2 Analysts have issued a InspireMD Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6.82 6.82 |
25%
25%
|
|
Gross Profit | 1.54 1.54 |
3%
3%
|
|
EBITDA | -30 -30 |
48%
48%
|
EBIT (Operating Income) EBIT | -30 -30 |
48%
48%
|
Net Profit | -28 -28 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
Head office | United States |
CEO | Marvin Slosman |
Employees | 66 |
Founded | 2005 |
Website | www.inspiremd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.